<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Posters Archive - Scholar Rock</title>
	<atom:link href="https://scholarrock.com/posters/feed/" rel="self" type="application/rss+xml" />
	<link>https://scholarrock.com/posters/</link>
	<description></description>
	<lastBuildDate>Thu, 07 Nov 2024 14:00:22 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.7.1</generator>

<image>
	<url>https://scholarrock.com/wp-content/uploads/2020/08/cropped-favicon-32x32.png</url>
	<title>Posters Archive - Scholar Rock</title>
	<link>https://scholarrock.com/posters/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>DRAGON trial: durable remission rate with the latent TGFβ1 inhibitor linavonkibart (SRK-181) and pembrolizumab in patients with immune checkpoint inhibitor–resistant advanced cancers</title>
		<link>https://scholarrock.com/posters/dragon-trial-durable-remission-rate-with-the-latent-tgf%ce%b21-inhibitor-linavonkibart-srk-181-and-pembrolizumab-in-patients-with-immune-checkpoint-inhibitor-resistant-advanced-cancers/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Thu, 07 Nov 2024 14:00:00 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=poster&#038;p=1203</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/posters/dragon-trial-durable-remission-rate-with-the-latent-tgf%ce%b21-inhibitor-linavonkibart-srk-181-and-pembrolizumab-in-patients-with-immune-checkpoint-inhibitor-resistant-advanced-cancers/">DRAGON trial: durable remission rate with the latent TGFβ1 inhibitor linavonkibart (SRK-181) and pembrolizumab in patients with immune checkpoint inhibitor–resistant advanced cancers</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/posters/dragon-trial-durable-remission-rate-with-the-latent-tgf%ce%b21-inhibitor-linavonkibart-srk-181-and-pembrolizumab-in-patients-with-immune-checkpoint-inhibitor-resistant-advanced-cancers/">DRAGON trial: durable remission rate with the latent TGFβ1 inhibitor linavonkibart (SRK-181) and pembrolizumab in patients with immune checkpoint inhibitor–resistant advanced cancers</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>SRK-439 Selectively Inhibits Myostatin to Promote Healthy Body Composition During Metformin Therapy</title>
		<link>https://scholarrock.com/posters/srk-439-selectively-inhibits-myostatin-to-promote-healthy-body-composition-during-metformin-therapy/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Mon, 04 Nov 2024 13:00:00 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=poster&#038;p=1201</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/posters/srk-439-selectively-inhibits-myostatin-to-promote-healthy-body-composition-during-metformin-therapy/">SRK-439 Selectively Inhibits Myostatin to Promote Healthy Body Composition During Metformin Therapy</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/posters/srk-439-selectively-inhibits-myostatin-to-promote-healthy-body-composition-during-metformin-therapy/">SRK-439 Selectively Inhibits Myostatin to Promote Healthy Body Composition During Metformin Therapy</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Longer-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with nonambulatory SMA: Results from the 48-month TOPAZ study</title>
		<link>https://scholarrock.com/posters/longer-term-efficacy-safety-and-patient-reported-outcomes-of-apitegromab-in-patients-with-nonambulatory-sma-results-from-the-48-month-topaz-study/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Fri, 11 Oct 2024 19:40:43 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=poster&#038;p=1196</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/posters/longer-term-efficacy-safety-and-patient-reported-outcomes-of-apitegromab-in-patients-with-nonambulatory-sma-results-from-the-48-month-topaz-study/">Longer-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with nonambulatory SMA: Results from the 48-month TOPAZ study</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/posters/longer-term-efficacy-safety-and-patient-reported-outcomes-of-apitegromab-in-patients-with-nonambulatory-sma-results-from-the-48-month-topaz-study/">Longer-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with nonambulatory SMA: Results from the 48-month TOPAZ study</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Apitegromab in spinal muscular atrophy: Baseline characteristics of participants enrolled in the phase 3 SAPPHIRE study</title>
		<link>https://scholarrock.com/posters/apitegromab-in-spinal-muscular-atrophy-baseline-characteristics-of-participants-enrolled-in-the-phase-3-sapphire-study/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Fri, 11 Oct 2024 19:39:14 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=poster&#038;p=1194</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/posters/apitegromab-in-spinal-muscular-atrophy-baseline-characteristics-of-participants-enrolled-in-the-phase-3-sapphire-study/">Apitegromab in spinal muscular atrophy: Baseline characteristics of participants enrolled in the phase 3 SAPPHIRE study</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/posters/apitegromab-in-spinal-muscular-atrophy-baseline-characteristics-of-participants-enrolled-in-the-phase-3-sapphire-study/">Apitegromab in spinal muscular atrophy: Baseline characteristics of participants enrolled in the phase 3 SAPPHIRE study</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>The Anti-Myostatin Antibody SRK-439 Promotes Healthy Body Composition in Combination with GLP-1RAs in a Mouse Model of Obesity</title>
		<link>https://scholarrock.com/posters/the-anti-myostatin-antibody-srk-439-promotes-healthy-body-composition-in-combination-with-glp-1ras-in-a-mouse-model-of-obesity/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Mon, 24 Jun 2024 10:59:35 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=poster&#038;p=1182</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/posters/the-anti-myostatin-antibody-srk-439-promotes-healthy-body-composition-in-combination-with-glp-1ras-in-a-mouse-model-of-obesity/">The Anti-Myostatin Antibody SRK-439 Promotes Healthy Body Composition in Combination with GLP-1RAs in a Mouse Model of Obesity</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/posters/the-anti-myostatin-antibody-srk-439-promotes-healthy-body-composition-in-combination-with-glp-1ras-in-a-mouse-model-of-obesity/">The Anti-Myostatin Antibody SRK-439 Promotes Healthy Body Composition in Combination with GLP-1RAs in a Mouse Model of Obesity</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>An Update on Scholar Rock&#8217;s Progress in SMA</title>
		<link>https://scholarrock.com/posters/an-update-on-scholar-rocks-progress-in-sma/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Wed, 12 Jun 2024 19:50:47 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=poster&#038;p=1179</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/posters/an-update-on-scholar-rocks-progress-in-sma/">An Update on Scholar Rock&#8217;s Progress in SMA</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/posters/an-update-on-scholar-rocks-progress-in-sma/">An Update on Scholar Rock&#8217;s Progress in SMA</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Phase1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1inhibitor, combined with pembrolizumab in anti-PD1 resistant patients with advanced solid tumors: Updated results of expansion phase</title>
		<link>https://scholarrock.com/posters/phase1-study-dragon-of-srk-181-linavonkibart-a-latent-tgf%ce%b21inhibitor-combined-with-pembrolizumab-in-anti-pd1-resistant-patients-with-advanced-solid-tumors-updated-results-of-expansion-phas/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Mon, 03 Jun 2024 20:00:17 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=poster&#038;p=1175</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/posters/phase1-study-dragon-of-srk-181-linavonkibart-a-latent-tgf%ce%b21inhibitor-combined-with-pembrolizumab-in-anti-pd1-resistant-patients-with-advanced-solid-tumors-updated-results-of-expansion-phas/">Phase1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1inhibitor, combined with pembrolizumab in anti-PD1 resistant patients with advanced solid tumors: Updated results of expansion phase</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/posters/phase1-study-dragon-of-srk-181-linavonkibart-a-latent-tgf%ce%b21inhibitor-combined-with-pembrolizumab-in-anti-pd1-resistant-patients-with-advanced-solid-tumors-updated-results-of-expansion-phas/">Phase1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1inhibitor, combined with pembrolizumab in anti-PD1 resistant patients with advanced solid tumors: Updated results of expansion phase</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Effect Of Apitegromab on Motor Function and Patient-reported Outcomes at 36 Months in Patients Aged 2–21 Years with Spinal Muscular Atrophy</title>
		<link>https://scholarrock.com/posters/effect-of-apitegromab-on-motor-function-and-patient-reported-outcomes-at-36-months-in-patients-aged-2-21-years-with-spinal-muscular-atrophy-2/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Sat, 23 Mar 2024 21:15:00 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=poster&#038;p=1171</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/posters/effect-of-apitegromab-on-motor-function-and-patient-reported-outcomes-at-36-months-in-patients-aged-2-21-years-with-spinal-muscular-atrophy-2/">Effect Of Apitegromab on Motor Function and Patient-reported Outcomes at 36 Months in Patients Aged 2–21 Years with Spinal Muscular Atrophy</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/posters/effect-of-apitegromab-on-motor-function-and-patient-reported-outcomes-at-36-months-in-patients-aged-2-21-years-with-spinal-muscular-atrophy-2/">Effect Of Apitegromab on Motor Function and Patient-reported Outcomes at 36 Months in Patients Aged 2–21 Years with Spinal Muscular Atrophy</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Disease Burden in Patients with Spinal Muscular Atrophy (SMA) Treated with Survival Motor Neuron (SMN)-Targeted Therapies: A Targeted Literature Review</title>
		<link>https://scholarrock.com/posters/disease-burden-in-patients-with-spinal-muscular-atrophy-sma-treated-with-survival-motor-neuron-smn-targeted-therapies-a-targeted-literature-review/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Mon, 04 Mar 2024 19:33:48 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=poster&#038;p=1165</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/posters/disease-burden-in-patients-with-spinal-muscular-atrophy-sma-treated-with-survival-motor-neuron-smn-targeted-therapies-a-targeted-literature-review/">Disease Burden in Patients with Spinal Muscular Atrophy (SMA) Treated with Survival Motor Neuron (SMN)-Targeted Therapies: A Targeted Literature Review</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/posters/disease-burden-in-patients-with-spinal-muscular-atrophy-sma-treated-with-survival-motor-neuron-smn-targeted-therapies-a-targeted-literature-review/">Disease Burden in Patients with Spinal Muscular Atrophy (SMA) Treated with Survival Motor Neuron (SMN)-Targeted Therapies: A Targeted Literature Review</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Effect of apitegromab on motor function and patient-reported outcomes at 36 months in patients aged 2–21 years with spinal muscular atrophy</title>
		<link>https://scholarrock.com/posters/effect-of-apitegromab-on-motor-function-and-patient-reported-outcomes-at-36-months-in-patients-aged-2-21-years-with-spinal-muscular-atrophy/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Mon, 04 Mar 2024 19:02:19 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=poster&#038;p=1166</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/posters/effect-of-apitegromab-on-motor-function-and-patient-reported-outcomes-at-36-months-in-patients-aged-2-21-years-with-spinal-muscular-atrophy/">Effect of apitegromab on motor function and patient-reported outcomes at 36 months in patients aged 2–21 years with spinal muscular atrophy</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/posters/effect-of-apitegromab-on-motor-function-and-patient-reported-outcomes-at-36-months-in-patients-aged-2-21-years-with-spinal-muscular-atrophy/">Effect of apitegromab on motor function and patient-reported outcomes at 36 months in patients aged 2–21 years with spinal muscular atrophy</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
